Pseudoprogression Manifesting as Recurrent Ascites with Anti-PD-1 Immunotherapy in Urothelial Bladder Cancer … – UroToday
|
Pseudoprogression Manifesting as Recurrent Ascites with Anti-PD-1 Immunotherapy in Urothelial Bladder Cancer …
UroToday April 10, 2018; Five anti-PD-1/L1 immunotherapies have been approved for advanced/metastatic urothelial bladder cancer since 2016, which has shifted drastically the way in which patients are treated. Longstanding experience with chemotherapy led to … |
